BioCentury
ARTICLE | Finance

Stars align for rare AMD

Why investors are backing Gemini to apply precision medicine in dry AMD

October 20, 2017 8:59 PM UTC

Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use the precision medicine approach that is common to cancer and rare diseases to target mutations in the complement system in dry age-related macular degeneration.

On Oct. 17, Gemini emerged from stealth to announce the A round, which was co-led by Atlas Venture, Lightstone Ventures and OrbiMed Advisors. The three firms also participated in an undisclosed seed financing for the company in 2016. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article